Table 2. Summary of antimalarial therapeutic efficacy studies, 9 countries in Africa, 2002–2007*.

Country	Sites	Treatments studied	Age of patients enrolled	Year	Total no. samples			ACTs introduced
					D0 + DF	D0	DF
Angola	Benguela, Zaire, Lunda Sul	AL, ASAQ, DP	6 mo–12 y	2015	379	379	0	2005
				2017	76	38	38	2005
Benin	Klouanmey, Djougou	AL	6–59 mo	2017	194	175	19	2004
DRC	Kabondo, Kapolowe, Rutshuru, Mikalayi, Kimpese	AL, ASAQ, DP	6–59 mo	2017–2018	633	317	316	2006
Guinea	Maferinyah, Labè	AL	6–59 mo	2016	432	409	23	2004–2005
Kenya	Siaya County	AL, DP	6–59 mo	2016–2017	417	325	92	2006
Malawi	Machinga, Nkhotakota, Karonga	AL, ASAQ	6–59 mo	2014	27	8	19	2007
Mali	Dioro, Sèlinguè	AL, ASAQ	2–59 mo	2015–2016	410	320	90	2006
Tanzania	Kibaha, Ujiji, Mkuzi, Mlimba	AL	6 mo–10 y	2016	417	345	72	2006
Zambia	Gwembe, Katete, Mansa	AL, DP	>6 mo	2016	263	263	0	2002
Total					3,248	2,579	669

*ACTs, artemisinin-based combination therapies; AL, artemether/lumefantrine; ASAQ, artesunate/amodiaquine; D0, day of enrollment (pretreatment); DF, day of failure; DP, dihydroartemisinin/piperaquine; DRC; Democratic Republic of the Congo.